Library
Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS
Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting
Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting
Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo
Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo
Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patien
Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patien
Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablativ e conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablativ e conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
Development of the Next Generation NKG2D CAR T-cell Manufacturing Process
Development of the Next Generation NKG2D CAR T-cell Manufacturing Process
Celyad Receives Additional €2.5 Million in Non-Dilutive Funding
Celyad Receives Additional €2.5 Million in Non-Dilutive Funding
Celyad Announces Board of Directors Evolution with New Appointment
Celyad Announces Board of Directors Evolution with New Appointment
Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region
Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region
Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights
Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights
Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting
Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting
Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients
Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients